Author:
da Cunha Mélanie Faria,Pranke Iwona,Sassi Ali,Schreiweis Christiane,Moriceau Stéphanie,Vidovic Dragana,Hatton Aurélie,Carlon Mariane Sylvia,Creste Geordie,Berhal Farouk,Prestat Guillaume,Freund Romain,Odolczyk Norbert,Jais Jean Philippe,Gravier-Pelletier Christine,Zielenkiewicz Piotr,Jullien Vincent,Hinzpeter Alexandre,Oury Franck,Edelman Aleksander,Sermet-Gaudelus Isabelle
Abstract
AbstractMutations in the Cystic Fibrosis Transmembrane Conductance Regulator gene (CFTR) are responsible for Cystic Fibrosis (CF). The most common CF-causing mutation is the deletion of the 508th amino-acid of CFTR (F508del), leading to dysregulation of the epithelial fluid transport in the airway’s epithelium and the production of a thickened mucus favoring chronic bacterial colonization, sustained inflammation and ultimately respiratory failure. c407 is a bis-phosphinic acid derivative which corrects CFTR dysfunction in epithelial cells carrying the F508del mutation. This study aimed to investigate c407 in vivo activity in the F508del Cftrtm1Eur murine model of CF. Using nasal potential difference measurement, we showed that in vivo administration of c407 by topical, short-term intraperitoneal and long-term subcutaneous route significantly increased the CFTR dependent chloride (Cl−) conductance in F508del Cftrtm1Eur mice. This functional improvement was correlated with a relocalization of F508del-cftr to the apical membrane in nasal epithelial cells. Importantly, c407 long-term administration was well tolerated and in vitro ADME toxicologic studies did not evidence any obvious issue. Our data provide the first in vivo preclinical evidence of c407 efficacy and absence of toxicity after systemic administration for the treatment of Cystic Fibrosis.
Funder
Vaincre La Mucoviscidose
Agence Nationale de la Recherche
Publisher
Springer Science and Business Media LLC
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献